Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Tough decisions' as Sobi gears up for new hemophilia launch

This article was originally published in Scrip

Executive Summary

Geoffrey McDonough, president and CEO of Swedish Orphan Biovitrum (Sobi), says the rare disease-focused company has been making launch preparations for Elocta, its recombinant clotting factor VIII hemophilia therapy, for two years now. However, in a bid to maintain focus on its more promising commercial prospects, Sobi has made some tough decisions in the past few months, he noted, speaking at the Jefferies Global Healthcare Conference in London this week.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts